Targeted chemo delivery could boost pancreatic cancer surgery success
NCT ID NCT07477418
First seen Mar 18, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This early-stage trial tests whether delivering a standard chemotherapy drug (gemcitabine) directly to the tumor through a special catheter can improve outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed by the targeted drug delivery before surgery. The main goal is to check safety and see if this approach helps surgeons remove the tumor completely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.